Core Viewpoint - GL Capital Management GP Limited has increased its stake in Ginkgo Bioworks (2190.HK) by acquiring 4.4 million shares at an average price of HKD 24 per share, totaling HKD 105.6 million, reflecting confidence in the company's operational stability and growth potential [1] Group 1: Shareholding and Investment - GL Capital Management GP Limited's latest shareholding after the increase is 20.5 million shares, representing a 6.09% ownership stake [1] - Other notable shareholders of Ginkgo Bioworks include Orbimed, Lake Bleu, and AIHC Capital, which are specialized investment firms focused on the Chinese healthcare sector [1] Group 2: Company Strategy and Future Outlook - Ginkgo Bioworks has been actively advancing its innovative product pipeline and expanding its core products' market coverage both domestically and internationally [1] - The company aims to enhance its global operational capabilities and continues to adhere to the philosophy of "Innovating for Life," with plans to increase investment in medical technology research and development [1] - Ginkgo Bioworks is committed to providing high-quality and affordable medical device products and solutions for patients worldwide [1]